Integra LifeSciences (NASDAQ:IART) Trading Up 8.7% - Time to Buy?

Key Points

• Integra LifeSciences' stock rose 8.7% to $13.86, despite trading volume declining by 68% compared to the average daily volume.
• Analyst ratings are mixed, with Wells Fargo and JPMorgan reducing their price targets significantly, leading to a consensus rating of "Hold" and an average target price of $18.63.
• The company reported earnings of $0.45 per share, surpassing expectations, while revenue for the quarter was down 0.6% year-over-year at $415.61 million.

Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report)'s stock price shot up 8.7% on Tuesday . The stock traded as high as $13.85 and last traded at $13.86. 327,602 shares traded hands during trading, a decline of 68% from the average session volume of 1,015,415 shares. The stock had previously closed at $12.75.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on IART. JMP Securities decreased their price target on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a report on Friday, May 9th. Wells Fargo & Company decreased their price target on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. decreased their price target on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. Four equities research analysts have rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $18.63.

Integra LifeSciences Stock Up 4.2%

The company has a current ratio of 1.23, a quick ratio of 0.73 and a debt-to-equity ratio of 1.18. The company has a 50-day simple moving average of $12.65 and a 200 day simple moving average of $16.74. The company has a market cap of $1.11 billion, a P/E ratio of -2.17, a P/E/G ratio of 0.80 and a beta of 1.16.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.43 by $0.02. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%. The business had revenue of $415.61 million for the quarter, compared to the consensus estimate of $395.06 million. During the same quarter in the prior year, the company earned $0.63 EPS. The business's revenue was down .6% compared to the same quarter last year. On average, equities analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current year.

Institutional Investors Weigh In On Integra LifeSciences

Institutional investors have recently added to or reduced their stakes in the stock. Sterling Capital Management LLC boosted its position in Integra LifeSciences by 821.7% during the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock valued at $49,000 after purchasing an additional 1,931 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its position in Integra LifeSciences by 205.9% during the second quarter. Caitong International Asset Management Co. Ltd now owns 3,132 shares of the life sciences company's stock valued at $38,000 after purchasing an additional 2,108 shares in the last quarter. AlphaQuest LLC bought a new stake in Integra LifeSciences during the second quarter valued at about $73,000. EMC Capital Management bought a new stake in Integra LifeSciences during the second quarter valued at about $75,000. Finally, CWM LLC boosted its position in Integra LifeSciences by 413.8% during the first quarter. CWM LLC now owns 6,664 shares of the life sciences company's stock valued at $147,000 after purchasing an additional 5,367 shares in the last quarter. Institutional investors own 84.78% of the company's stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.